Skip to main content
Journal cover image

Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.

Publication ,  Journal Article
Bagai, A; Armstrong, PW; Stebbins, A; Mahaffey, KW; Hochman, JS; Weaver, WD; Patel, MR; Granger, CB; Lopes, RD
Published in: Am Heart J
November 2013

BACKGROUND: Left ventricular end-diastolic pressure (LVEDP) is frequently measured during primary percutaneous coronary intervention (PCI). However, little is known of this measurement's utility in predicting outcomes or informing treatment decisions. We sought to determine the prognostic value of LVEDP measured during primary PCI for ST-segment elevation myocardial infarction (STEMI). METHODS: We studied 1,909 (33.2%) of 5,745 STEMI patients in whom LVEDP was measured during primary PCI in the APEX-AMI trial. Cox regression analysis was used to evaluate whether LVEDP was an independent predictor of mortality and the composite of death, cardiogenic shock, or congestive heart failure (CHF) at 90 days. RESULTS: The median (25th, 75th percentiles) LVEDP level was 22 mm Hg (16, 29); compared with patients with LVEDP ≤ 22 mm Hg, those with LVEDP > 22 mm Hg had higher rates of CHF (7.3% vs 3.1%, P < .001), cardiogenic shock (4.6% vs 1.7%, P < .001), and death (4.1% vs 2.2%, P = .014) at 90 days. After multivariable adjustment, LVEDP was associated with increased risk of mortality through 90 days (adjusted hazard ratio 1.22, 95% CI 1.02-1.46, per 5-mmHg increase, P = .044) and the composite of death, cardiogenic shock, or CHF within the first 2 days (adjusted hazard ratio 1.40, 95% CI 1.23-1.59, per 5-mm Hg increase, P < .001), but not from day 3 to 90 (P = .25). CONCLUSIONS: Left ventricular end-diastolic pressure measured during primary PCI for STEMI is an independent predictor of inhospital and longer term cardiovascular outcomes. Measuring LVEDP may be useful to stratify patient risk and guide postinfarct treatment.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2013

Volume

166

Issue

5

Start / End Page

913 / 919

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Survival Rate
  • Single-Chain Antibodies
  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bagai, A., Armstrong, P. W., Stebbins, A., Mahaffey, K. W., Hochman, J. S., Weaver, W. D., … Lopes, R. D. (2013). Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study. Am Heart J, 166(5), 913–919. https://doi.org/10.1016/j.ahj.2013.08.006
Bagai, Akshay, Paul W. Armstrong, Amanda Stebbins, Kenneth W. Mahaffey, Judith S. Hochman, W Douglas Weaver, Manesh R. Patel, Christopher B. Granger, and Renato D. Lopes. “Prognostic implications of left ventricular end-diastolic pressure during primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: Findings from the Assessment of Pexelizumab in Acute Myocardial Infarction study.Am Heart J 166, no. 5 (November 2013): 913–19. https://doi.org/10.1016/j.ahj.2013.08.006.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

November 2013

Volume

166

Issue

5

Start / End Page

913 / 919

Location

United States

Related Subject Headings

  • Ventricular Function, Left
  • Treatment Outcome
  • Survival Rate
  • Single-Chain Antibodies
  • Risk Factors
  • Proportional Hazards Models
  • Prognosis
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Middle Aged